UBS analyst Paul Gong downgrades NIO (NYSE:NIO) from Buy to Neutral and lowers the price target from $32 to $13.
Genetic Technologies Reports Q3 2021 Revs A$99K
Genetic Technologies Limited (NASDAQ:GENE, ", Company", , ", GTG", )))), a global leader in Genomics based tests in health, wellness and serious disease, is pleased to provide its Quarterly Business